DNA-crosslinker cisplatin eradicates bacterial persister cells

Biotechnology and Bioengineering

Volumn 113, Issue 9, 2016, Pages 1984-1992

  Chowdhury, Nityananda ^a   Wood, Thammajun L ^a   Martínez Vázquez, Mariano ^b   García Contreras, Rodolfo ^c   Wood, Thomas K ^a,d  

^a The Center for Nanotechnology Education and Utilization   (United States)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^d PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

biofilm; cisplatin; DNA crosslinking; persistence

Indexed keywords

BACTERIA; BIOFILMS; CELLS; CROSSLINKING; CYTOLOGY; DNA; ESCHERICHIA COLI;

BROAD-SPECTRUM ACTIVITIES; CIS-PLATIN; DNA-CROSSLINKING; ESCHERICHIA COLI K-12; MICROBIAL INFECTIONS; PERSISTENCE; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

PLATINUM COMPOUNDS;

BUSULFAN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DYNEMICIN A; MELPHALAN; MITOMYCIN; TIRAPAZAMINE;

ARTICLE; BACTERIAL CELL; BACTERIAL CLEARANCE; BACTERIAL GROWTH; BACTERIAL PERSISTER CELL; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BIOFILM; CELL KILLING; CONTROLLED STUDY; DNA CROSS LINKING; DORMANCY; DRUG EFFICACY; DRUG MECHANISM; ENTEROHEMORRHAGIC ESCHERICHIA COLI; ESCHERICHIA COLI K 12; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

EID: 84979759134     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.25963     Document Type: Article

References (51)

1. Archer NK, Mazaitis MJ, Costerton JW, Leid JG, Powers ME, Shirtliff ME. 2011. Staphylococcus aureus biofilms: Properties, regulation, and roles in human disease. Virulence 2:445–459.
2. Baba T, Ara T, Hasegawa M, Takai Y, Okumura Y, Baba M, Datsenko KA, Tomita M, Wanner BL, Mori H. 2006. Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: The Keio collection. Mol Syst Biol 2:2006.0008.
3. Beck DJ, Brubaker RR. 1973. Effect of cis-platinum(II) diamminodichloride on wild type and deoxyribonucleic acid repair deficient mutants of Escherichia coli. J Bacteriol 116:1247–1252.
4. Bradner WT. 2001. Mitomycin C: A clinical update. Cancer Treat Rev 27:35–50.
5. Cervantes-Garcia E, Garcia-Gonzalez R, Resendiz-Albor A, Salazar-Schettino PM. 2015. Infections of diabetic foot ulcers with methicillin-resistant Staphylococcus aureus. Int J Low Extrem Wounds 14:44–49.
6. Chowdhury N, Kwan BW, Wood TK. 2016. Persistence increases in the absence of the alarmone guanosine tetraphosphate by reducing cell growth. Sci Rep 6:20519.
7. Chvalova K, Brabec V, Kasparkova J. 2007. Mechanism of the formation of DNA-protein cross-links by antitumor cisplatin. Nucleic Acids Res 35:1812–1821.
8. Conlon BP, Nakayasu ES, Fleck LE, LaFleur MD, Isabella VM, Coleman K, Leonard SN, Smith RD, Adkins JN, Lewis K. 2013. Activated ClpP kills persisters and eradicates a chronic biofilm infection. Nature 503:365–370.
9. Cross A, Allen JR, Burke J, Ducel G, Harris A, John J, Johnson D, Lew M, MacMillan B, Meers P, Skalova R, Wenzel R, Tenney J. 1983. Nosocomial infections due to Pseudomonas aeruginosa: Review of recent trends. Rev Infect Dis 5(Suppl 5):S837–S845.
10. Dedduwa-Mudalige GN, Chow CS. 2015. Cisplatin targeting of bacterial ribosomal RNA hairpins. Int J Mol Sci 16:21392–21409.
11. DeLeon S, Clinton A, Fowler H, Everett J, Horswill AR, Rumbaugh KP. 2014. Synergistic interactions of Pseudomonas aeruginosa and Staphylococcus aureus in an in vitro wound model. Infect Immun 82:4718–4728.
12. Denny WA, Wilson WR. 2000. Tirapazamine: A bioreductive anticancer drug that exploits tumour hypoxia. Expert Opin Investig Drugs 9:2889–2901.
13. Donegan K, Matyac C, Seidler R, Porteous A. 1991. Evaluation of methods for sampling, recovery, and enumeration of bacteria applied to the phylloplane. Appl Environ Microbiol 57:51–56.
14. Eastman A. 1987. The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol Ther 34:155–166.
15. Emadi A, Jones RJ, Brodsky RA. 2009. Cyclophosphamide and cancer: Golden anniversary. Nat Rev Clin Oncol 6:638–647.
16. Fauvart M, De Groote VN, Michiels J. 2011. Role of persister cells in chronic infections: Clinical relevance and perspectives on anti-persister therapies. J Med Microbiol 60:699–709.
17. Fletcher M. 1977. The effects of culture concentration and age, time, and temperature on bacterial attachment to polystyrene. Can J Microbiol 23:1–6.
18. Frei E, Holland JF. 2003. Cancer medicine-6 review: A companion to Holland-Frei Cancer medicine-6. Hamilton, ON: B.C. Decker.
19. García-Contreras R, Peréz-Eretza B, Jasso-Chávez R, Lira-Silva E, Roldán-Sánchez JA, González-Valdez A, Soberón-Chávez G, Coria-Jiménez R, Martínez-Vázquez M, Alcaraz LD, Maeda T, Wood TK. 2015. High variability in quorum quenching and growth inhibition by furanone C-30 in Pseudomonas aeruginosa clinical isolates from cystic fibrosis patients. Pathog Dis 73:ftv040.
20. Hall MD, Telma KA, Chang KE, Lee TD, Madigan JP, Lloyd JR, Goldlust IS, Hoeschele JD, Gottesman MM. 2014. Say no to DMSO: Dimethylsulfoxide inactivates cisplatin, carboplatin, and other platinum complexes. Cancer Res 74:3913–3922.
21. Heo YJ, Chung IY, Cho WJ, Lee BY, Kim JH, Choi KH, Lee JW, Hassett DJ, Cho YH. 2010. The major catalase gene (katA) of Pseudomonas aeruginosa PA14 is under both positive and negative control of the global transactivator OxyR in response to hydrogen peroxide. J Bacteriol 192:381–390.
22. Hofsteenge N, van Nimwegen E, Silander OK. 2013. Quantitative analysis of persister fractions suggests different mechanisms of formation among environmental isolates of E. coli. BMC Microbiol 13:25.
23. Jacobs MA, Alwood A, Thaipisuttikul I, Spencer D, Haugen E, Ernst S, Will O, Kaul R, Raymond C, Levy R, Chun-Rong L, Guenthner D, Bovee D, Olson MV, Manoil C. 2003. Comprehensive transposon mutant library of Pseudomonas aeruginosa. Proc Natl Acad Sci USA 100:14339–14344.
24. Joyce K, Saxena S, Williams A, Damurjian C, Auricchio N, Aluotto S, Tynan H, Demain AL. 2010. Antimicrobial spectrum of the antitumor agent, cisplatin. J Antibiot (Tokyo) 63:530–532.
25. Kaper JB. 1998. Enterohemorrhagic Escherichia coli. Curr Opin Microbiol 1:103–108.
26. Konishi M, Ohkuma H, Matsumoto K, Tsuno T, Kamei H, Miyaki T, Oki T, Kawaguchi H, VanDuyne GD, Clardy J. 1989. Dynemicin A, a novel antibiotic with the anthraquinone and 1,5-diyn-3-ene subunit. J Antibiot (Tokyo) 42:1449–1452.
27. Kwan BW, Chowdhury N, Wood TK. 2015. Combatting bacterial infections by killing persister cells with mitomycin C. Environ Microbiol 17:4406–4414.
28. Kwan BW, Valenta JA, Benedik MJ, Wood TK. 2013. Arrested protein synthesis increases persister-like cell formation. Antimicrob Agents Chemother 57:1468–1473.
29. Lewis K. 2007. Persister cells, dormancy and infectious disease. Nat Rev Microbiol 5:48–56.
30. Lewis K. 2008. Multidrug tolerance of biofilms and persister cells. Curr Top Microbiol Immunol 322:107–131.
31. Li Y, Wang Z, Ma X, Shao B, Gao X, Zhang B, Xu G, Wei Y. 2014. Low-dose cisplatin administration to septic mice improves bacterial clearance and programs peritoneal macrophage polarization to M1 phenotype. Pathog Dis 72:111–123.
32. Liberati NT, Urbach JM, Miyata S, Lee DG, Drenkard E, Wu G, Villanueva J, Wei T, Ausubel FM. 2006. An ordered, nonredundant library of Pseudomonas aeruginosa strain PA14 transposon insertion mutants. Proc Natl Acad Sci USA 103:2833–2838.
33. Loewen PC. 1984. Isolation of catalase-deficient Escherichia coli mutants and genetic mapping of katE, a locus that affects catalase activity. J Bacteriol 157:622–626.
34. Loewen PC, Triggs BL, George CS, Hrabarchuk BE. 1985. Genetic mapping of katG, a locus that affects synthesis of the bifunctional catalase-peroxidase hydroperoxidase I in Escherichia coli. J Bacteriol 162:661–667.
35. Rangel-Vega A, Bernstein LR, Mandujano-Tinoco EA, Garcia-Contreras SJ, Garcia-Contreras R. 2015. Drug repurposing as an alternative for the treatment of recalcitrant bacterial infections. Front Microbiol 6:282.
36. Rasko DA, Sperandio V. 2010. Anti-virulence strategies to combat bacteria-mediated disease. Nat Rev Drug Discov 9:117–128.
37. Rodriguez RL, Tait RC. 1983. Recombinant DNA techniques: An introduction. Menlo Park, CA: The Benjamin/Cummings Publiching Company, Inc.
38. Rosenberg B, Vancamp L, Krigas T. 1965. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 205:698–699.
39. Sambrook J, Fritsch EF, Maniatis T. 1989. Molecular cloning: A laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
40. Sanders CC. 1988. Ciprofloxacin: In vitro activity, mechanism of action, and resistance. Rev Infect Dis 10:516–527.
41. Shah Z, Mahbuba R, Turcotte B. 2013. The anticancer drug tirapazamine has antimicrobial activity against Escherichia coli, Staphylococcus aureus and Clostridium difficile. FEMS Microbiol Lett 347:61–69.
42. Sharma B, Brown AV, Matluck NE, Hu LT, Lewis K. 2015. Borrelia burgdorferi, the causative agent of lyme disease, forms drug-tolerant persister cells. Antimicrob Agents Chemother 59:4616–4624.
43. Sperandio V, Torres AG, Giron JA, Kaper JB. 2001. Quorum sensing is a global regulatory mechanism in enterohemorrhagic Escherichia coli O157:H7. J Bacteriol 183:5187–5197.
44. Tomasz M. 1995. Mitomycin C: Small, fast and deadly (but very selective). Chem Biol 2:575–579.
45. Ueda A, Attila C, Whiteley M, Wood TK. 2009. Uracil influences quorum sensing and biofilm formation in Pseudomonas aeruginosa and fluorouracil is an antagonist. Microb Biotechnol 2:62–74.
46. Ueda A, Wood TK. 2009. Connecting quorum sensing, c-di-GMP, pel polysaccharide, and biofilm formation in Pseudomonas aeruginosa through tyrosine phosphatase TpbA (PA3885). PLoS Pathog 5:e1000483.
47. Walz JM, Avelar RL, Longtine KJ, Carter KL, Mermel LA, Heard SO. 2010. Anti-infective external coating of central venous catheters: A randomized, noninferiority trial comparing 5-fluorouracil with chlorhexidine/silver sulfadiazine in preventing catheter colonization. Crit Care Med 38:2095–2102.
48. Wolcott R, Dowd S. 2011. The role of biofilms: Are we hitting the right target?. Plast Reconstr Surg 127:28S–35S.
49. Wood TK, Knabel SJ, Kwan BW. 2013. Bacterial persister cell formation and dormancy. Appl Environ Microbiol 79:7116–7121.
50. Wu N, He L, Cui P, Wang W, Yuan Y, Liu S, Xu T, Zhang S, Wu J, Zhang W, Zhang Y. 2015. Ranking of persister genes in the same Escherichia coli genetic background demonstrates varying importance of individual persister genes in tolerance to different antibiotics. Front Microbiol 6:1003.
51. Zhen W, Link CJ, Jr., O'Connor PM, Reed E, Parker R, Howell SB, Bohr VA. 1992. Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol Cell Biol 12:3689–3698.